clinical dataAbivax delivers Phase 3 ulcerative colitis win, but safety concerns trigger market sell-offParisian Abivax shared positive topline results for its Phase 3 trial in ulcerative colitis. Its investigational oral, first-in-class miR-124 enhancer, dubbed obefazimod, met all primary and secondary … more ➔
Elnur Amikishiyev-stock.adobe.comStart-upA fresh start for Molecular Health: technology core becomes start-up LuceraA restart from within: Molecular Health is becoming Lucera. After years of shifting corporate fortunes, a substantial part of Heidelberg-based Molecular Health is continuing in a new form. An investor … more ➔
clinical dataGreywolf reports early responses with oral ERAP1 inhibitor in solid tumoursOxford-based Greywolf Therapeutics has reported early clinical activity for its first-in-class oral ERAP1 inhibitor GRWD5769 in combination with the anti-PD-1 antibody cemiplimab across six solid tumour … more ➔
oncologyASCO: Immatics posts data on PRAME pipeline ahead of pivotal readoutImmatics has published a series of updates on its PRAME pipeline, using the American Society for Clinical Oncology (ASCO) Annual Meeting to share data on its lead candidate and next-generation progr … more ➔
Clinical trialOculis drops plans for diabetic macular edema drug after Phase III missSwiss ophthalmology biotech Oculis has suffered a major setback for its most advanced ophthalmology programme after two pivotal Phase III trials of OCS-01 eye drops in diabetic macular edema failed to … more ➔
M&AServier buys Edgewise muscular dystrophy business for up to US$2.65bnFrench pharmaceutical group Servier has agreed to acquire sevasemten and the muscular dystrophy business built around it from US biotech Edgewise Therapeutics Inc. in a transaction worth up to US$2.65bn, … more ➔
ROGER HARRIS/SCIENCE PHOTO LIBRA-stock.adobe.comM&AT-CURX buys Pantherna as the race for in vivo CAR-T gathers paceT-CURX acquires Pantherna: does this mark the start of a new race for the next generation of CAR-T therapies? The Würzburg- and Munich-based CAR-T company T-CURX is acquiring the Berlin-based mRNA and … more ➔
FinancingOSE Immunotherapeutics turns to IRIS for €19.3m bridge financingFrench immunotherapy developer OSE Immunotherapeutics has signed a term sheet for a flexible bridge equity financing with IRIS Capital Investment, giving the Nantes- and Paris-based biotech access to … more ➔
Nuclidium AGRadiopharmaceuticalsExtra boost for Nuclidium: financing round reaches €115 millionBasel-based Nuclidium AG has secured an additional tranche for its ongoing Series B financing round, bringing the total to approximately €115 million. The theranostics company is developing copper-based … more ➔
GSKGSK reports 19% functional cure rate for near-approval hepatitis B drugGSK has linked its chronic hepatitis B drug candidate to a 19% functional cure rate across a pair of Phase III trials, clearing the bar it set for clinical relevance. more ➔
Elnur Amikishiyev-stock.adobe.com
ROGER HARRIS/SCIENCE PHOTO LIBRA-stock.adobe.com
Nuclidium AG